CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
The CDC25 phosphatases are cell cycle regulators known to play an important role in cancer cell growth. Increased expression of CDC25B has been reported in tumors of different tissue origins, including non-small cell lung carcinoma (NSCLC). We analyzed primary tumors and corresponding healthy lung tissues from 177 patients with NSCLC for relative expression levels of CDC25B by reverse transcription-polymerase chain reaction, with the dual aims of investigating the relationships between CDC25B expression and angiogenesis as well as prognosis. Eighty-one (45.76%) of the 177 patients with NSCLC overexpressed the CDC25B gene; there was no significant difference in CDC25B expression among sex, age, T or N status, or clinical stages of NSCLC. Concerning the possible involvement of CDC25B in angiogenesis, high expression of CDC25B correlated with positive expression of endothelin-1 (chi(2) test; P = .0002), one of the major angiogenic factors in NSCLC. A significant association was also found with the number of intratumoral microvessels (chi(2) test; P = .03). Statistical analysis of survival data revealed that elevated CDC25B expression was significantly associated with shorter survival in terms of both overall survival and disease-free interval (P = .04 for both), maintaining its independent prognostic role in a Cox proportional hazards model (P = .009). A rich and varied engagement of many cellular pathways could cause or maintain a cancer; our study may offer insights into these mechanisms in lung cancer, suggesting that CDC25B might play an important role in the angiogenic process and in determining the prognosis of patients with NSCLC.